文献速递妇科肿瘤

新辅助化疗(NACT)增加上皮性卵巢癌(EOC)的免疫浸润和程序性死亡配体1(PD-L1)表达

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
PubMed 文献 · Ann Oncol · 2017-01-01

该回顾性研究评估了新辅助化疗对上皮性卵巢癌肿瘤浸润淋巴细胞及PD-L1表达的影响。结果显示NACT后间质TILs中位值从20%升至30%,PD-L1阳性免疫细胞比例从30%升至53%。高间质TILs在化疗前后均为无进展生存的独立预后因素。

要点

  • NACT后间质TILs中位值从20%升至30%(P=0.0005),51%患者升高。
  • NACT后PD-L1阳性免疫细胞比例从30%升至53%(P=0.026)。
  • 化疗前和化疗后高间质TILs均为PFS独立预后因素。

核心结论

  • 在上皮性卵巢癌中,间质TILs水平在诊断时具有预后价值,且在新辅助化疗后仍保持预后价值。
  • 新辅助化疗后TILs和PD-L1表达增加。
  • 评估新辅助化疗后肿瘤的免疫参数可能有助于筛选适合免疫治疗试验的患者。

研究设计与样本

  • 回顾性识别具有序贯样本(化疗前、化疗后或复发)的上皮性卵巢癌患者。
  • TILs在全切片上评估;间质TILs以间质面积百分比评分,高间质TILs定义为≥50%;上皮内TILs半定量评分(0-3),高上皮内TILs定义为≥2。
  • PD-L1评估可用样本较少,阳性截断值为≥5%染色。
  • 配对化疗前后样本共83例可用于间质TILs分析;PD-L1评估化疗前50例、化疗后51例。

主要发现

  • 诊断时所有肿瘤均可检测到间质TILs(范围2-90%,中位20%),22%(25/113)显示高间质TILs。
  • 配对化疗前后样本(N=83)中,新辅助化疗后间质TILs中位值从20%升至30%(P=0.0005);51%(42/83)升高,25%降低,24%稳定。
  • 化疗后间质TILs可预测无铂间期(PFI),PFI≥6个月患者化疗后间质TILs显著高于PFI<6个月患者(28% vs 18%,P=0.026);化疗前间质TILs无预测价值。
  • 诊断时23%显示高上皮内TILs,新辅助化疗后33%显示上皮内TILs增加。
  • PD-L1阳性免疫细胞肿瘤比例化疗前为30%(15/50),化疗后为53%(27/51)(P=0.026);配对肿瘤中63%的PD-L1阴性肿瘤在新辅助化疗后转为阳性;顺铂在PD-L1阴性上皮性卵巢癌细胞系中诱导PD-L1表达。

关键数值与推荐

  • 高间质TILs定义为间质面积百分比≥50%。
  • 高上皮内TILs定义为半定量评分≥2。
  • PD-L1阳性截断值为≥5%染色。

临床怎么用

  • 作者认为,评估新辅助化疗后肿瘤的免疫参数可能有助于筛选适合免疫治疗试验的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphocytic infiltration at diagnosis is prognostic in EOC, however, the impact of NACT on tumour infiltrating lymphocytes (TILs) or PD-L1 expression remains poorly described. PATIENTS AND METHODS: Patients with EOC and sequential samples (pre-NACT, post-NACT or relapse) were retrospectively identified. TILs were evaluated on whole sections; stromal TILs (sTILs) scored as percentage of stromal area with high sTILs defined as ≥50%; intra-epithelial TILs (ieTILs) scored semi-quantitatively (0-3) with high ieTILs ≥2. A smaller number were available for PD-L1 evaluation, cut-off for positivity was ≥5% staining. RESULTS: sTILs were detected in all tumours at diagnosis (range 2-90%, median 20%), with 22% (25/113) showing high sTILs. Among evaluable paired pre/post-NACT samples (N = 83), an overall increase in median sTILs from 20% to 30% was seen following NACT (P = 0.0005); individually the impact of NACT varied with sTILs increasing in 51% (42/83), decreasing in 25%, and stable in 24%. Post-NACT sTILs were predictive of platinum-free interval (PFI), patients with PFI ≥6 months had significantly higher post-NACT sTILs (sTILs 28% versus 18% for PFI <6 months, P = 0.026); pre-NACT sTILS were not predictive. At diagnosis, 23% showed high ieTILs, and following NACT 33% showed increasing ieTILs. Proportion of tumours with PD-L1-positive immune cells was 30% (15/50) pre-NACT and 53% (27/51) post-NACT (P = 0.026). Among paired tumours, 63% of PD-L1-negative tumours became positive after NACT, furthermore cisplatin induced PD-L1 expression in PD-L1-negative EOC cell lines. On multivariate analysis, high sTILs both pre- and post-NACT were independent prognostic factors for progression-free survival (PFS) (HR 0.49, P = 0.02 and HR 0.60, P = 0.05, respectively). No prognostic impact of ieTILs or PD-L1 expression was detected. CONCLUSIONS: In EOC, sTILs levels are prognostic at diagnosis and remain prognostic after NACT. TILs and PD-L1 expression increase following NACT. Evaluation of immune parameters in the post-NACT tumour may help select patients for immunotherapy trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mesnage SJL, Auguste A, Genestie C, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017. PMID: 27864219. doi:10.1093/annonc/mdw625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。